EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC

BACKGROUND: Several EGFR-tyrosine kinase inhibitors (TKIs), such as gefitinib (Gef), have been used as effective clinical therapies for patients with non-small cell lung cancer (NSCLC). However, due to acquired resistance, the efficacy of Gef treatment is severely blocked. Our preliminary study foun...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Jiao, Chang, Cuicui, Chen, Yuhua, Bi, Fangfang, Ji, Chen, Liu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668247/
https://www.ncbi.nlm.nih.gov/pubmed/31440060
http://dx.doi.org/10.2147/OTT.S209441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668247/
https://www.ncbi.nlm.nih.gov/pubmed/31440060
http://dx.doi.org/10.2147/OTT.S209441

Ejemplares similares